A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Public ClinicalTrials.gov record NCT06525220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Study identification
- NCT ID
- NCT06525220
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 699 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2024 (Actual)
- Primary completion
- Jan 2028 (Estimated)
- Completion
- Jul 2030 (Estimated)
- Last update posted
- Sep 25, 2026
2024 – 2030
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 164 | Mobile | Alabama | 36607 | — |
| Site 36 | La Jolla | California | 92037 | — |
| Site 27 | Los Angeles | California | 90033 | — |
| Site 16 | Palo Alto | California | 94304 | — |
| Site 19 | Newark | Delaware | 19713 | — |
| Site 108 | Washington D.C. | District of Columbia | 20010 | — |
| Site 14 | Fort Myers | Florida | 33901 | — |
| Site 8 | Orlando | Florida | 32827 | — |
| Site 21 | St. Petersburg | Florida | 33705 | — |
| Site 20 | West Palm Beach | Florida | 33401 | — |
| Site 171 | Atlanta | Georgia | 30322 | — |
| Site 197 | Chicago | Illinois | 60611 | — |
| Site 50 | Chicago | Illinois | 60637 | — |
| Site 2 | Louisville | Kentucky | 40202 | — |
| Site 162 | Baton Rouge | Louisiana | 70809 | — |
| Site 155 | Minneapolis | Minnesota | 55417 | — |
| Site 168 | St Louis | Missouri | 63108 | — |
| Site 94 | Hackensack | New Jersey | 07601 | — |
| Site 6 | Albuquerque | New Mexico | 87131 | — |
| Site 113 | Durham | North Carolina | 27710 | — |
| Site 118 | Winston-Salem | North Carolina | 27157 | — |
| Site 191 | Cleveland | Ohio | 44195 | — |
| Site 43 | Philadelphia | Pennsylvania | 19104 | — |
| Site 153 | Philadelphia | Pennsylvania | 19107 | — |
| Site 154 | Philadelphia | Pennsylvania | 19114 | — |
| Site 89 | Chattanooga | Tennessee | 37404 | — |
| Site 115 | Memphis | Tennessee | 38103 | — |
| Site 88 | Nashville | Tennessee | 37203 | — |
| Site 22 | Austin | Texas | 78745 | — |
| Site 1 | Houston | Texas | 77030 | — |
| Site 18 | Plano | Texas | 75075 | — |
| Site 17 | Sugar Land | Texas | 77479 | — |
| Site 15 | Tyler | Texas | 75702 | — |
| Site 10 | Salt Lake City | Utah | 84112 | — |
| Site 12 | Blacksburg | Virginia | 24060 | — |
| Site 23 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 166 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06525220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06525220 live on ClinicalTrials.gov.